Andre Goy, M.D. is HMH Physician in Chief, Hackensack Meridian Health Oncology Services and Chairman and Chief Physician Officer of John Theurer Cancer Center (“JTCC”) at Hackensack University Medical Center as well as Academic Chairman – Oncology at the Hackensack Meridian Health School of Medicine.
HMH Oncology Program encompasses 18 hospitals system including John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC), a member of the National Cancer Institute (NCI)-designated Lombardi Comprehensive Cancer Center Consortium. JTCC provides the largest oncology program in New Jersey and is also a member of the Memorial Sloan Kettering - Hackensack Meridian Health partnership. Dr. Goy is also professor and Founding chair of the Department of Oncology at the Hackensack Meridian School of Medicine at Seton Hall University as well as Professor of Medicine at Georgetown University in Washington, DC.
Dr. Goy is widely known for his work in lymphoma, particularly in drug development in mantle cell lymphoma and other aggressive lymphomas. His research interest also includes the identification of prognostic markers and better ways to stratify patients with lymphoma. Dr. Goy has served on the steering committee for the NCI for lymphoma and on the Scientific Advisory Board of the Lymphoma Research Foundation. Dr. Goy and his team have been involved with the NCI for almost a decade in the development of new forms of immunotherapy, including checkpoint inhibitors in lymphoma and CAR T-cell therapy, leading to the first approval of CAR-T cells in lymphoma, in November 2017.
Dr. Goy believes that a true revolution is happening in cancer medicine, which will be driven by cell-based therapies /immunotherapy, precise medicine, earlier detection, analytics and connectivity. The bioinformatics platform developed at JTCC – called COTA – uses a unique classification system compressing all relevant individual patient data into a usable code (CNA). This digital architecture allows us to track individual outcome, optimize decisions in cancer care, and hence reduce adverse variance in order to improve outcome at the individual level, while lowering costs for the population along the way and supporting value-based care initiatives.
Dr. Goy has published more than 180 peer reviewed papers and serves as reviewer for many journals in the field including the New England Journal of Medicine, the Journal of Clinical Oncology, and Blood, the American Society of Hematology Journal, among others. He has been the co-chair of the Global Council on the Future of Health and Healthcare for the World Economic Forum since 2015. He believes that we are at an inflection point in medicine due to unprecedented combination of rapid progress in science and discovery, but also technology which will help reshape both health and healthcare delivery.
Dr. Goy received his medical degree from University Joseph Fourier in Grenoble, France before completing his training in hematology oncology in Paris at the Faculté of Medicine Cochin Port Royal. While there he also received a Master’s degree in Tumor Immunology from Pasteur Institute and Curie University Paris VI as well as a Master’s degree in Experimental Oncology from University Kremlin Bicetre.
Dr. Goy was on faculty at Memorial Sloan-Kettering and M.D. Anderson Cancer Center before joining John Theurer Cancer Center in 2005. Dr. Goy has been leading the Lymphoma Program at JTCC, he became Chair and Director of JTCC in 2012, and has been appointed as Physician in Chief for Hackensack Meridian Health, the largest, most comprehensive and truly integrated health care network in New Jersey, with 18 hospitals from Bergen to Ocean counties.
RSS